

# Generic Contrast Agents

Our portfolio is growing to serve you better. Now you have a *choice*.



[VIEW CATALOG](#)

# AJNR

## **Diffusion Tensor Imaging of Patients with HIV and Normal-appearing White Matter on MR Images of the Brain**

Christopher G. Filippi, Aziz M. Ulug, Elizabeth Ryan, Steven J. Ferrando and Wilfred van Gorp

This information is current as of May 13, 2025.

*AJNR Am J Neuroradiol* 2001, 22 (2) 277-283  
<http://www.ajnr.org/content/22/2/277>

## Diffusion Tensor Imaging of Patients with HIV and Normal-appearing White Matter on MR Images of the Brain

Christopher G. Filippi, Aziz M. Uluğ, Elizabeth Ryan, Steven J. Ferrando, and Wilfred van Gorp

**BACKGROUND AND PURPOSE:** HIV enters the CNS early in the course of infection and produces neuropsychiatric impairment throughout the course of illness, which preferentially affects the subcortical white matter. The development of a neuroimaging marker of HIV may allow for the earliest detection of cognitive impairment. The purpose of this study was to determine whether MR diffusion tensor imaging can detect white matter abnormalities in patients who have tested positive for HIV.

**METHODS:** Ten patients with HIV (eight men and two women; mean age, 42 years) underwent MR imaging of the brain with MR diffusion tensor imaging, which included routine fluid-attenuated inversion recovery and fast spin-echo T2-weighted imaging. Diffusion constants and anisotropy indices were calculated from diffusion tensor maps. Peripheral viral load, Centers for Disease Control staging, and cluster of differentiation 4 levels were determined.

**RESULTS:** All patients had normal results of MR imaging of the brain, except for mild atrophy. Four of 10 patients had undetectable viral loads. These patients were receiving highly active antiretroviral therapy. The diffusion constant and anisotropy were normal. Four of 10 patients had viral loads between 10,000 and 200,000. Diffusion anisotropy in the splenium and genu was significantly decreased ( $P < .02$ ). The diffusion constant of the subcortical white matter was elevated in the frontal and parietooccipital lobes (11%). Two of 10 patients had viral loads  $>400,000$ . Anisotropy of the splenium was half normal ( $P < .0004$ ) and of the genu was decreased 25% ( $P < .002$ ). The average diffusion constant was diffusely elevated in the subcortical white matter.

**CONCLUSION:** Calculating the diffusion constant and anisotropy in the subcortical white matter and corpus callosum in patients with HIV detected abnormalities despite normal-appearing white matter on MR images and nonfocal neurologic examinations. Patients with the highest diffusion constant elevations and largest anisotropy decreases had the most advanced HIV disease. Patients with the lowest viral load levels, who had normal anisotropy and diffusion constants, were receiving highly active antiretroviral therapy.

HIV is neurotrophic, and most patients who have tested positive for HIV develop neuropsychiatric impairment during the course of illness, which ranges from HIV-associated mild cognitive motor disorder to HIV-associated dementia (1–5). What triggers the transition from an asymptomatic patient to one with cognitive impairment is unknown, but

the development of a neuroimaging marker of HIV disease in the CNS may allow for the earliest possible detection of cognitive impairment. This could be used, in theory, to measure response to antiretroviral therapy.

Recent proton MR spectroscopic studies have shown some promise as potential markers of HIV disease in the CNS. These techniques have shown metabolic abnormalities in patients who have tested positive for HIV that seem to correlate with early cognitive impairment (6). However, proton MR spectroscopy is not in routine clinical use. This technique is limited by the relatively long imaging time for each voxel sampled (minimum of 3–5 min), the need for skilled, accurate voxel placement or a dedicated spectroscopist, and patient compliance (no movement). Therefore, we investigated MR diffusion imaging, an emerging MR technique

Received February 8, 2000; accepted after revision July 31.

From the Departments of Radiology (C.G.F., A.M.U.), Psychology (E.R., W.v.G.), and Psychiatry (S.J.F.), New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY.

Address reprint requests to Christopher G. Filippi, MD, New York Presbyterian Hospital-Weill Medical College of Cornell University, Department of Radiology, Box 141, 525 East 68th Street, New York, NY 10021.

that is in routine clinical use. We hypothesized that diffusion tensor imaging can detect abnormalities in the corpus callosum and subcortical white matter of patients with HIV, which may correlate with either the clinical stage of disease or viral load level.

## Methods

During an 8-month period, 19 patients with HIV (13 men and six women; mean age, 44 years) who had undergone MR diffusion tensor imaging were prospectively identified. Nine of these patients were excluded for the following reasons: six had periventricular white matter disease suggestive of progressive multifocal leucoencephalopathy (PML) or HIV encephalopathy, two exhibited excessive motion during the study, and one had claustrophobia and failed to complete the examination. The remaining 10 patients (eight men and two women; mean age, 42 years) underwent nonfocal neurologic examinations and had normal results of MR imaging of the brain, with the exception of age-inappropriate atrophy. The images were interpreted by a neuroradiologist without any clinical knowledge of the patients other than HIV-positive status. In addition to routine clinical MR pulse sequences, these patients underwent MR imaging that included MR diffusion tensor imaging. Of these 10 patients, four had presented with headache, four with changes in mental status, one with a questionable history of seizure that was not witnessed by the patient's clinician, and one with vertigo. Four of the 10 patients were not receiving protease inhibitors. The remaining six patients were receiving various combinations of highly active antiretroviral therapy (HAART). Cluster of differentiation 4 (CD4) levels and viral loads (HIV messenger RNA) in the blood were obtained from all patients. Centers for Disease Control staging was determined from clinical information that was obtained from chart review.

All 10 patients underwent routine MR imaging on a 1.5-T magnet using a standard head coil. Routine sequences were performed, including sagittal T1-weighted (500–600/12/1 [TR/TE/excitations]), axial fast spin-echo T2-weighted (3000/91/1), axial fluid-attenuated inversion recovery (10002/172/1) with an inversion time of 2200 ms, axial T1-weighted (500/14/1), and axial diffusion-weighted echo-planar (6000/99–100/1) imaging. In addition, a diffusion tensor pulse sequence, which can measure the diffusion in any arbitrary direction, was then used. The sequence is a single-shot, multisection, spin-echo, echo-planar pulse sequence (6000/100/1), using a matrix size of  $128 \times 128$ , 5-mm interleaved data acquisition, 30 sections to cover the whole brain, and a field of view of 22 cm. Using this sequence, we collected the diffusion-weighted images in seven directions (X, Y, Z, X+Y, X+Z, Y+Z, X+Y+Z), with a maximum b value of 820 s/mm<sup>2</sup> per gradient axis. The data acquisition time for this part of the examination is 5 to 10 minutes, depending on the number of diffusion-weighted images acquired. For most of the cases, we used a total of 22 diffusion-weighted images with differing b values.

On a workstation, an orientation-independent diffusion map ( $D_{av} = \text{Trace}/3 = [D_{xx} + D_{yy} + D_{zz}]/3$ ) was calculated for each pixel from the diffusion-weighted images. Using a multivariate fitting routine, in C, we calculated six diffusion maps corresponding to the six independent elements of the diffusion tensor, D. From these diffusion maps, we calculated an orientationally invariant average diffusion map and an orientationally invariant anisotropy map using anisotropy index,  $UA_{surf}$ . This anisotropy index is calculated by comparing the  $D_{av}$  with the  $D_{surf}$ , which is a new diffusion constant obtained from the surface of the diffusion ellipsoid (7, 8). This anisotropy index, which has high sensitivity, is defined in terms of diffusion coefficients as follows:

$$UA_{surf} = \sqrt{\left(\frac{D_{surf}}{D_{av}} - 1\right)^2}$$

where

$$D_{av} = (D_{xx} + D_{yy} + D_{zz})/3 \quad \text{and}$$

$$D_{surf} = [(D_{xx}D_{yy} + D_{xx}D_{zz} + D_{yy}D_{zz} - D_{xy}D_{xy} - D_{xz}D_{xz} - D_{yz}D_{yz})/3]^{1/2}$$

Diffusion anisotropy ( $UA_{surf}$ ) is scaled between 0 to 1, where 0 corresponds to isotropic diffusion and 1 to fully anisotropic unidirectional diffusion.

There is no standard, accepted way to measure anisotropy. Different groups have chosen to use different anisotropy measures, such as relative anisotropy index or fractional anisotropy to describe anisotropy (9–11). Recent studies have shown that different anisotropy measures have different sensitivities in describing tissue anisotropy, and the anisotropy index, ( $UA_{surf}$ ), is the most sensitive measurement for the detection of anisotropy changes in white matter fiber tracts (7, 12, 13). Because we were interested in white matter fiber tracts, we chose to use this anisotropy index.

For each patient, average diffusion constants were calculated from the following regions of interest using voxel sizes of 3 to 5 mm: the frontal lobe subcortical white matter bilaterally, the parietooccipital subcortical white matter bilaterally, the centrum semiovale bilaterally, and the genu and splenium of the corpus callosum (Fig 1). These values were compared with normative data of adults, one of whom has been reported in the literature by one of the authors in this study (A.M.U.) (7). Two of the authors measured the diffusion constants and anisotropy values without any clinical knowledge regarding the patients except for the HIV-positive status. The mean values of the diffusion constant and anisotropy for the patients with lowest, intermediate, and highest viral load levels were compared using a Student's two-tailed *t* test, assuming unequal variance and using a *P* level of <.05 for significance.

## Results

Table 1 provides a summary of the clinical data of these patients with HIV, including CD4 counts, viral load levels, and Centers for Disease Control staging. Tables 2 and 3 list the means and SD for the measurements of the diffusion constant ( $D_{av}$ ) and anisotropy ( $UA_{surf}$ ) that were obtained in the subcortical white matter and corpus callosum.

All patients had normal results of MR imaging of the brain, except for mild atrophy, and all patients had nonfocal neurologic examinations. Six of 10 patients were receiving HAART.

Four patients had undetectable peripheral viral load levels (<400 copies/mm<sup>3</sup>). These patients had an average CD4 count of 489, and all were receiving HAART. Using Centers for Disease Control criteria, two had stage A1 disease and two had stage C3 disease (AIDS). In these patients, the diffusion constant ( $D_{av}$ ) in the frontal lobe subcortical white matter was only slightly elevated (4% increase) to  $0.78 \times 10^{-5}$  cm<sup>2</sup>/s. In the parietooccipital subcortical white matter and centrum semiovale, the  $D_{av}$  was normal. In these patients, there was an elevation of the  $D_{av}$  in the genu of the corpus callosum to  $0.83 \times 10^{-5}$  cm<sup>2</sup>/s, which is 11% higher than expected. However, the splenium of the corpus callosum showed a decrease in  $D_{av}$  to  $0.76 \times 10^{-5}$




FIG 1. Voxel placements are shown on the diffusion tensor sequence for the determination of the average diffusion constant ( $D_{av}$ ).

FIG 2. Graph plots values for the anisotropy in the genu and splenium of the corpus callosum versus the measured peripheral viral load levels (HIV messenger RNA copies/mm<sup>3</sup>). An inverse trend is observed. As the viral load levels increase, the anisotropy of these structures decreases.

TABLE 1: Clinical data

Patient (no.)	Sex	CD4 Count	Viral Load HIV mRNA (copies/mm <sup>3</sup> )*	CDC Stage	Anti-retroviral Drug Therapy (ART)†
1	M	299.0	<400	C3	1, 5–7
2	F	969.0	<400	A1	1, 9–10
3	M	54.0	<400	C3	9–12
4	M	634.0	<400	A1	2, 8, 13
5	F	386.0	14,000	B2	None
6	M	1536.0	35,000	A1	None
7	M	20.0	54,000	C3	1–4
8	M	144.0	150,000	C1	None
9	M	30.0	412,000	C1	2–4, 8
10	M	6.0	1,000,000	C3	None

\* <400 HIV mRNA copies/mm<sup>3</sup> indicates undetectable viral load levels.

† ART: 1 = D4T, 2 = 3TC, 3 = Indinavir, 4 = Viramune, 5 = Delavirdine, 6 = Zalcitabine, 7 = Zalcitabine, 8 = AZT, 9 = Zalcitabine, 10 = ddI, 11 = Combivir, 12 = Sustiva, 13 = Crixivan.

TABLE 2: Diffusion constant ( $D_{av}$ ) measurements ( $10^{-5}$  cm<sup>2</sup>/s)\*

$D_{av}$ ( $10^{-5}$ cm <sup>2</sup> /s)	Viral Load Levels (HIV mRNA copies/mm <sup>3</sup> )			
	<400 n = 4	10,000–200,000 n = 4	>400,000 n = 2	Normal† n = 5
Frontal subcortical WM	0.78 ± 0.02	0.84 ± 0.01	1.07 ± 0.04	0.77 ± 0.03
Parietooccipital WM	0.75 ± 0.01	0.81 ± 0.02	1.13 ± 0.05	0.77 ± 0.03
Centrum semiovale	0.72 ± 0.04	0.70 ± 0.06	0.86 ± 0.06	0.75 ± 0.07
Genu corpus callosum	0.83 ± 0.05	0.80 ± 0.07	1.03 ± 0.04	0.75 ± 0.10
Splenium corpus callosum	0.76 ± 0.11	0.81 ± 0.09	1.10 ± 0.08	0.88 ± 0.10

\* Means and standard deviations are reported.

† Uluğ AM, van Zijl PCM. Orientation-independent Diffusion Imaging Without Tensor Diagonalization: Anisotropy Definitions Based on Physical Attributes of the Diffusion Ellipsoid. *J Magn Reson Imaging* 1999;9:804–813.

TABLE 3: Anisotropy measurements\*

	Viral Load Levels (HIV mRNA copies/mm <sup>3</sup> )			
	<400 n = 4	10,000–200,000 n = 4	>400,000 n = 2	Normal† n = 5
Genu corpus callosum	0.24 ± 0.03	0.20 ± 0.02	0.18 ± 0.01	0.24 ± 0.05
Splenium corpus callosum	0.28 ± 0.04	0.23 ± 0.03	0.14 ± 0.02	0.27 ± 0.04

\* Means and standard deviations are reported.

† Uluğ AM, van Zijl PCM. Orientation-independent Diffusion Imaging Without Tensor Diagonalization: Anisotropy Definitions Based on Physical Attributes of the Diffusion Ellipsoid. *J Magn Reson Imaging* 1999;9:804–813.

cm<sup>2</sup>/s. Notably, the anisotropy within the genu and splenium was normal (Tables 2 and 3).

Four patients had detectable viral load levels between 10,000 and 200,000 HIV messenger RNA copies/mm<sup>3</sup>. These patients had an average CD4 count of 522, and only one was receiving HAART. Of these patients, one had Centers for Disease Control stage A1 disease, another had stage B2, and two had full-blown AIDS (stages C1 and C3). These patients, who had intermediate viral load levels, had elevations in the diffusion constant in the frontal subcortical white matter ( $0.84 \times 10^{-5}$  cm<sup>2</sup>/s), which represents an increase of 12% compared with normal. In the parietooccipital subcortical white matter, a smaller 8% increase was noted ( $D_{av}$  of  $0.81 \times 10^{-5}$  cm<sup>2</sup>/s). None of these increases, however, were statistically significant compared with normal values. The  $D_{av}$  in the centrum semiovale was normal. In the genu of the corpus callosum, the  $D_{av}$  was slightly elevated to  $0.80 \times 10^{-5}$  cm<sup>2</sup>/s (6% increase) but the anisotropy decreased by 17% ( $UA_{surf}$  of .20), which was statistically significant ( $P < .02$ ). The  $D_{av}$  within the splenium of the corpus callosum is decreased to  $0.81 \times 10^{-5}$  cm<sup>2</sup>/s, but the anisotropy was 0.23, which represents an 18% decrease compared with normal values, and this was statistically significant ( $P < .02$ ) (Tables 2 and 3).

Two patients had significantly high viral load levels (>400,000 copies HIV messenger RNA/mm<sup>3</sup>). These patients had very low CD4 counts of 6 and 30, respectively, and one was not receiving HAART. Both patients had Centers for Disease Control stage C (AIDS). These patients had large increases in the  $D_{av}$  at all measured locations despite a normal-appearing brain on MR images. The frontal subcortical white matter was increased to  $1.07 \times 10^{-5}$  cm<sup>2</sup>/s, which is 44% above normal. In the parietooccipital subcortical white matter, the  $D_{av}$  was elevated to  $1.13 \times 10^{-5}$  cm<sup>2</sup>/s, which represents an increase of 51%. In the centrum semiovale, the  $D_{av}$  was elevated by 23% ( $0.86 \times 10^{-5}$  cm<sup>2</sup>/s). In the genu of the corpus callosum, the  $D_{av}$  was elevated to  $1.03 \times 10^{-5}$  cm<sup>2</sup>/s, and, in the splenium of the corpus callosum, the  $D_{av}$  was  $1.10 \times 10^{-5}$  cm<sup>2</sup>/s, which was of statistical significance ( $P < .02$ ). The anisotropy of the genu was decreased to 0.18, which is a 25% decrease from normal and is statistically significant ( $P < .002$ ). The anisotropy of the splenium of the corpus callosum

was decreased to 0.14, which is a 50% decrease from normal and is of a high degree of statistical significance ( $P < .0004$ ) (Tables 2 and 3).

In the measurements of the diffusion constant, there were no differences detected regarding right versus left side of the brain. Thus, single means are indicated for the frontal and parietooccipital subcortical white matter, the centrum semiovale, and the genu and splenium of the corpus callosum.

## Discussion

Early in the course of infection, HIV enters the CNS and produces neuropsychiatric impairment throughout the course of illness for most patients with AIDS, which ranges from HIV-associated mild cognitive motor disorder to HIV-associated dementia (1–5). These disorders combine cognitive (primarily attention, speed of information processing, and learning efficiency), motor, and behavioral symptoms, which suggest that the virus preferentially targets the subcortical white matter. Neuropathologic studies have shown histopathologic changes in the subcortical white matter, including multinucleated giant cells, astrogliosis, and myelin pallor (3, 4, 14–16).

Recent evidence suggests that elevations in the CNS viral load are associated with HIV-related neurocognitive disorders (16–19). Further, there is evidence of both genotypic and phenotypic differences in the strains of HIV detected in the CNS compared with those in the peripheral circulation (17). This evidence supports the concept that the CNS is an independent “reservoir” or “sanctuary” for HIV, particularly in the later stages of the disease when neuropsychiatric disorders are most likely to occur (20). The concept that the CNS acts as a reservoir for HIV is important relative to antiretroviral therapy, because sufficient blood brain-barrier penetration would be needed if antiretroviral therapy were to be used to treat cognitive disorders (21).

The recent development of protease inhibitors has significantly decreased disease progression and mortality (5). Combination therapy, which uses both nucleoside analog reverse transcriptase inhibitors, such as azidothymidine, and protease inhibitors, has currently become the treatment of choice for patients with HIV. During the past year, reports have emerged showing that patients receiving



HAART have experienced reductions in CSF viral load levels (22, 23), reversal of white matter lesions on MR images (5), and improvements in neuropsychological test performance (24). However, other studies have documented progressive neurologic impairment despite the use of HAART and despite low viral load levels (25). Because most currently available protease inhibitors, with the exception of indinavir, do not have good blood brain-barrier penetration, it raises concerns that despite improvements in general health, patients receiving HAART will continue to experience neurocognitive decline (26). Because the CNS is likely a reservoir site for HIV, this could allow for the development of viral resistance and reseeding the peripheral circulation with drug-resistant virus.

The development of a neuroimaging marker for HIV-associated neuropathologic changes in the CNS may allow for the earliest possible detection of cognitive impairment, and, in theory, it could be used to measure response to HAART. In this study, we showed that abnormalities in the subcortical white matter and corpus callosum on MR diffusion tensor images could be detected for patients with HIV who had normal-appearing white matter on their MR images of the brain. The largest decreases in anisotropy in the corpus callosum and the largest elevations in the diffusion constant ( $D_{av}$ ) in the subcortical white matter occurred in patients who had the most advanced HIV disease with the highest viral load levels and lowest CD4 counts (Fig 2 [page 279]). In this set of patients, the  $D_{av}$  of the splenium was significantly elevated ( $P < .02$ ) and the anisotropy of the genu ( $P < .002$ ) and splenium ( $P < .0004$ ) were both significantly decreased. The patients with HIV who had nearly normal  $D_{av}$  and normal anisotropy had the lowest peripheral viral load levels and highest CD4 counts, on average. Patients with intermediate viral load levels (10,000–200,000 copies of HIV messenger RNA) had elevations in the  $D_{av}$  of 8% to 12% in the subcortical white matter but statistically significant decreases in anisotropy of 17% to 18% ( $P < .02$  for genu,  $P < .02$  for splenium) compared with the group of patients whose values were normal. In general, as viral load levels rise and CD4 counts decline, these patients had increases in the  $D_{av}$  and declines in the anisotropy. Thus, the diffusion constant ( $D_{av}$ ) and diffusion anisotropy may be useful neuroimaging markers for HIV disease.

Although the four patients with intermediate viral load levels had the highest mean CD4 count of 522, this reflects that one of these patients, who had early HIV disease (stage A1), had a relatively high peripheral viral load (35,000 copies of HIV messenger RNA/mm<sup>3</sup>) and a very high CD4 count of 1536.0. If this datum point were not included, the mean CD4 count for these patients would be 183.0, which is significantly lower compared with the mean CD4 count of patients with the lowest viral load levels, who would be expected to have higher CD4 counts. Even with the inclusion of this datum

point, as CD4 counts decline, there is a corresponding rise in the diffusion constant and decline in anisotropy.

In most of the patients with HIV, there was a greater elevation in the  $D_{av}$  in the subcortical white matter of the frontal lobe region when compared with the parietooccipital subcortical white matter, which may reflect a predilection for frontal white matter involvement in direct HIV infection in the CNS. In diffusion MR imaging, a loss of normal cell membrane homeostasis, which changes the net translational movement of water across cell membranes, has been hypothesized to create the signal abnormalities observed on MR images (27, 28). This can be quantified from the ADC maps, and this value, the diffusion constant or  $D_{av}$ , can reveal changes in white matter that are not seen on routine MR images of the brain (27, 28). In HIV-associated dementia or mild cognitive motor disorder, the subcortical white matter is preferentially affected (1–4, 14–16), and this may explain the changes in the diffusion constant that we observed in the subcortical white matter. In both these groups of patients, the  $D_{av}$  of the centrum semiovale was normal, which may signify that this area of white matter is affected later by HIV or may be more resistant to HIV infection.

With routine diffusion-weighted imaging, one assesses overall changes in the degree of diffusion, which intentionally eliminates the effects of tissue anisotropy (8). However, tissue microstructure is affected by the motion of water molecules on this scale, which determines the degree of anisotropy (8). One can acquire diffusion-sensitive (diffusion tensor) images in which this directional information is measured. By determining the anisotropy of white matter fiber tracts, which are highly ordered and have distinct directions, one can make inferences regarding the integrity of white matter fiber microstructure (8).

In this study, both the patients with intermediate and high viral load levels had statistically significant decreases in the measured anisotropy of the genu and splenium of the corpus callosum. The decreases in anisotropy that we have observed in this study would imply microscopic damage to these fiber tracts despite their normal appearance on macroscopic MR images of the brain. This may be explained in that HIV-associated dementia and mild cognitive motor disorder are thought to be disease processes in which there is preferential involvement of the white matter (1–4, 14–16).

Patients with undetectable viral load levels who were receiving HAART had normal anisotropy in both the genu and splenium of the corpus callosum. However, the diffusion constant was not normal in the patients with undetectable viral load levels. There was an elevation in the diffusion constant in the genu, which implies lack of restriction to water translation across this white matter fiber tract. This may simply represent an increase in the amount of water in the extracellular compartment despite nor-

mal-appearing T2-weighted and fluid-attenuated inversion recovery images. One could speculate that this represents myelin damage, which occurs in association with HIV infection in the CNS, because the myelin shows pallor on autopsy studies (15).

In patients with undetectable viral load levels, the splenium of the corpus callosum showed an apparent decrease in the diffusion constant to  $0.76 \times 10^{-5} \text{cm}^2/\text{s}$ . This value could be within the lower limits of normal, because the normative data for the  $D_{av}$  of the splenium was  $0.88 \times 10^{-5} \text{cm}^2/\text{s} \pm 0.10$  and the SD of this measurement shows a relatively wider range of variability for this measurement as compared with others. If this represents a real decrease in the measured  $D_{av}$ , more restriction to the normal translation of water in the splenium is implicated. The reason for this observation is unclear. Histopathologic studies of HIV infection of the brain have shown that there is an inflammatory response initiated early in the course of the disease (15). In theory, this inflammatory response could create a local hypercellular environment, which could impose more restrictions than normal to water diffusion. In general, for these patients, as viral load increased, there was a corresponding increase in the diffusion constant and decrease in anisotropy within the splenium.

Three of four patients with intermediate viral load levels and one of the patients with the highest viral load levels were not receiving HAART. All of these patients had marked elevations in the  $D_{av}$  in all locations measured and statistically significant decreases in the anisotropy of the genu and splenium despite normal-appearing white matter on MR images. Conversely, the patients with normal values who had the lowest viral load levels were all receiving HAART. It is not clear whether HAART can reverse abnormalities in the  $D_{av}$  or anisotropy. However, it seems that those patients who receive HAART have healthier white matter, because these patients have normal diffusion constants and anisotropy values indicative of normal translation of water molecules across myelin membranes, which implies integrity to the underlying white matter fiber tracts. To determine the effect of HAART on the diffusion constant and anisotropy of white matter fiber tracts, which are targeted by the virus when it gains access to the CNS, it will be important to study protease inhibitor-naïve patients who are going to begin HAART. A longitudinal, prospective study, which correlates CSF viral load levels, neuropsychological testing, quantification of drug levels, and MR diffusion tensor imaging findings may help to determine whether MR diffusion tensor imaging can act as a neuroimaging outcome measure of HAART efficacy.

### Conclusion

In summary, in patients who have tested positive for HIV who have normal-appearing white matter on MR images of the brain, calculating the diffu-

sion constant and anisotropy can detect abnormalities within the subcortical white matter and corpus callosum. Patients who had the highest elevations in the diffusion constant and the largest decreases in anisotropy had the most advanced HIV disease, as manifested by high peripheral viral load levels and low CD4 counts. Furthermore, most of these patients were not receiving HAART. Because diffusion tensor MR imaging can detect abnormalities missed by routine MR imaging, MR diffusion tensor imaging may have a role as a marker of HIV disease progression or HAART efficacy.

### References

1. Simpson DM, Berger JR. **Neurological manifestations of HIV infection.** *Med Clin North Am* 1996;80:1363-1394
2. Heaton RK, Grant I, Butters N, et al. **The HNRC 500: neuropsychology of HIV infection at different disease stages.** *J Int Neuropsychol Soc* 1995;3:231-251
3. van Gorp WG, Baerwald JP, Ferrando SJ, McElhiney MC, Rabkin JG. **The relationship between employment and neuropsychological impairment in HIV infection.** *J Int Neuropsychol Soc* 1999;5:534-539
4. Bencherif B, Rottenberg DA. **Neuroimaging and AIDS dementia complex.** *AIDS* 1998;12:233-244
5. Filippi CG, Sze G, Farber SJ, Shamanesh M, Selwyn P. **Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after initiation of protease inhibitor therapy.** *Radiology* 1998;206:491-499
6. Chang L, Ernst T, Leonido-Yee M, et al. **Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.** *Neurology* 1999;53:782-789
7. Uluğ AM, van Zijl PCM. **Orientation-independent diffusion imaging without tensor diagonalization: anisotropy definitions based on physical attributes of the diffusion ellipsoid.** *J Magn Reson Imaging* 1999;9:804-813
8. Uluğ AM, Moore DF, Bojko AS, Zimmerman RD. **Clinical use of diffusion-tensor imaging for diseases causing neuronal and axonal damage.** *AJNR Am J Neuroradiol* 1999;20:1044-1048
9. Shimony JS, McKinstry RC, Akbudak E, et al. **Quantitative diffusion-tensor anisotropy brain MR imaging: normative human data and anatomic analysis.** *Radiology* 1999;212:770-784
10. Pierpaoli C, Jezzard P, Basser PJ, Barnett A, DiChiro G. **Diffusion MR imaging of the human brain.** *Radiology* 1996;201:637-648
11. Pierpaoli C, Basser PJ. **Toward a quantitative assessment of diffusion anisotropy.** *Magn Reson Med* 1996;36:893-906
12. Armitage PA, Bastin ME. **Selecting an appropriate anisotropy index for displaying diffusion tensor imaging data with improved contrast and sensitivity.** *Magn Reson Med* 2000;44:117-121
13. Papadakis NG, Xing D, Houston GC, et al. **A study of rotationally invariant and symmetric indices of diffusion anisotropy.** *Magn Reson Med* 1999;17:881-892
14. van Gorp WG, Mandelkern MA, Gee M, et al. **Cerebral metabolic dysfunction in AIDS: findings in a sample with dementia and without dementia.** *J Neuropsychiatry Clin Neurosci* 1992;4:280-287
15. Kure K, Llena JF, Lyman WD, et al. **Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains.** *Hum Pathol* 1991;22(7):700-710
16. Brew BJ, Pemberton L, Cunningham P, Law M. **Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage.** *J Infect Dis* 1997;175:963-966
17. DiStefano M, Monno L, Fiore JR, et al. **Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype.** *AIDS* 1998;12:737-743
18. Ellis RJ, Hsia K, Spector SA, et al. **Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome.** *Ann Neurol* 1997;42:679-688
19. McArthur JC, McClernon DR, Cronin MF, et al. **Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain.** *Ann Neurol* 1997;42:689-698

20. Price RW, Strapans S. **Measuring the viral load in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection.** *Ann Neurol* 1997;42:675–678
21. Portegies P. **HIV-1, the brain, and combination therapy (letter).** *Lancet* 1995;346:1244–1245
22. Gisslen M, Hagberg L, Svennerholm B, Norkrans G. **HIV-1 RNA is not detectable in the cerebrospinal fluid during antiretroviral combination therapy.** *AIDS* 1997;11:1194
23. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. **HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine, and indinavir.** *AIDS* 1998;12:114–116
24. Ferrando SJ, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. **Highly active antiretroviral treatment (HAART) in HIV infection: benefits for neuropsychological function.** *AIDS* 1998;12:F65–F70
25. Pialoux G, Fournier S, Moulignier A, Poveda JD, Clavel F, Dupont B. **Central nervous system as a sanctuary site for HIV-1 infection despite treatment with zidovudine, lamivudine, and indinavir (letter).** *AIDS* 1997;11:1302–1303
26. Stahle L, Martin C, Svensson JO, Sonnerberg A. **Indinavir in the cerebrospinal fluid of HIV-1 infected patients.** *Lancet* 1997;350:1823
27. Moseley ME, Kucharczyk J, Mintorovitch J, et al. **Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats.** *AJNR Am J Neuroradiol* 1990;11:423–429
28. Uluğ AM, Beauchamp N, Bryan RN, van Zijl PCM. **Absolute quantitation of diffusion constants in human stroke.** *Stroke* 1997;28:483–490.